Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Balance Sheet and Financial Position
DVA logo

DaVita Raises 2026 Earnings Guidance as Revenue Per Treatment Climbs to $417.59

DVA8-KFiling Date: 5/5/2026
DaVita Inc.
Description

What this story covers

DaVita's Q1 2026 results show 6% revenue growth from higher rates, despite flat volumes. Strong cash flow funded 403 million dollars in share buybacks, prompting an increase in full-year earnings per share guidance.

Story snapshot

CompanyDaVita Inc.
TickerDVA
VariantStandard detailed
Duration13:47
Filing type8-K
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0000927066-26-000060
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in